Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.75 |
| ▸ | KRAS | P01116 | 5/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.64 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067722 | 0.93 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL18769114 | 0.93 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL851357 | 0.93 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL29429843 | 0.93 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21742884 | 0.92 | TGM2 (0.73) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21715326 | 0.92 | KRAS (0.73) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21742885 | 0.92 | TGM2 (0.73) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21742886 | 0.92 | TGM2 (0.75) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21742887 | 0.92 | TGM2 (0.75) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21742905 | 0.91 | TGM2 (0.74) | TGM2KRASNT5EFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | claimed |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9845500-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160244822-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation | 2016-08-25 | — | — | US | disclosed |
| US-9243284-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140127781-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-8648179-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130102050-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2013-04-25 | — | — | US | disclosed |
| US-8314216-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | Life Technologies Corporation (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100216122-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS | Life Technologies Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-20070172860-A1 | Enzymatic nucleic acid synthesis: compositions and methods | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172869-A1 | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172859-A1 | Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1354064-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | Visigen Biotechnologies, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2002044425-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6399335-B1 | MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | RNGTT, PPA1, PNP | TGM2 1058/4885KRAS 1461/4885NT5E 47/4885 |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | RNGTT, PPA1, PNP | TGM2 1137/4885KRAS 1464/4885NT5E 54/4885 |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | TGM2 1030/4885KRAS 1543/4885NT5E 47/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | TGM2 2003/4885KRAS 811/4885NT5E 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.